Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aliskiren Monotherapy Results in the Greatest and the Least Blood Pressure Lowering in Patients With High- and Low-Baseline PRA Levels, Respectively
Alice Stanton, Patrick Dicker, Eoin O’Brien
American Journal of Hypertension (2009) Vol. 22, Iss. 9, pp. 954-957
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Hypertension
Luuk te Riet, Joep H.M. van Esch, Anton J.M. Roks, et al.
Circulation Research (2015) Vol. 116, Iss. 6, pp. 960-975
Open Access | Times Cited: 611
Pressor Responses to Antihypertensive Drug Types
M. H. Alderman, Hillel W. Cohen, J. E. Sealey, et al.
American Journal of Hypertension (2010) Vol. 23, Iss. 9, pp. 1031-1037
Open Access | Times Cited: 61
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals
Jasper J. Brugts, Aaron Isaacs, Moniek PM de Maat, et al.
Journal of Hypertension (2010) Vol. 29, Iss. 3, pp. 509-519
Closed Access | Times Cited: 53
Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials
Selçuk Şen, Soner Sabırlı, Tolga Özyiğit, et al.
Therapeutic Advances in Chronic Disease (2013) Vol. 4, Iss. 5, pp. 232-241
Open Access | Times Cited: 37
Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System
Pitchai Balakumar, Gowraganahalli Jagadeesh
Journal of Cardiovascular Pharmacology (2010) Vol. 56, Iss. 5, pp. 570-579
Closed Access | Times Cited: 43
The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?
AH Jan Danser
Hypertension Research (2009) Vol. 33, Iss. 1, pp. 4-10
Open Access | Times Cited: 41
Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage
Heiko Funke‐Kaiser, Frank S. Zollmann, Jan H. Schefe, et al.
Hypertension Research (2009) Vol. 33, Iss. 2, pp. 98-104
Open Access | Times Cited: 40
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
José Alfie, Lucas S. Aparicio, W. D.
Reviews on Recent Clinical Trials (2011) Vol. 6, Iss. 2, pp. 134-146
Closed Access | Times Cited: 38
Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses
Bei Sun, Jonathan S. Williams, Luminita H. Pojoga, et al.
Journal of the Renin-Angiotensin-Aldosterone System (2011) Vol. 12, Iss. 4, pp. 564-571
Open Access | Times Cited: 27
Recent changes in the landscape of combination RAS blockade
Benjamin J Epstein, Steven M. Smith, Rushab Choksi
Expert Review of Cardiovascular Therapy (2009) Vol. 7, Iss. 11, pp. 1373-1384
Closed Access | Times Cited: 26
New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren
Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi‐Mito, et al.
Journal of Pharmacological Sciences (2010) Vol. 113, Iss. 4, pp. 296-300
Open Access | Times Cited: 23
Effects of Aliskiren‐Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients
Tomohiko Kanaoka, Kouichi Tamura, Masato Ohsawa, et al.
Journal of Clinical Hypertension (2012) Vol. 14, Iss. 8, pp. 522-529
Open Access | Times Cited: 17
Individualization of Antihypertensive Drug Treatment
Giuseppe Mancia, Guıdo Grassı
Diabetes Care (2013) Vol. 36, Iss. Supplement_2, pp. S301-S306
Open Access | Times Cited: 16
How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?
Gowraganahalli Jagadeesh, Pitchai Balakumar, Norman Stockbridge
Cellular Signalling (2012) Vol. 24, Iss. 8, pp. 1583-1591
Closed Access | Times Cited: 15
Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats
Norihito Moniwa, Jasmina Varagić, Sarfaraz Ahmad, et al.
Therapeutic Advances in Cardiovascular Disease (2012) Vol. 6, Iss. 1, pp. 15-29
Open Access | Times Cited: 15
Renin-Angiotensin System Phenotyping as a Guidance Toward Personalized Medicine for ACE Inhibitors: can the Response to ACE Inhibition be Predicted on the Basis of Plasma Renin or ACE?
Joyce E.M. Schilders, Haiyan Wu, Frans Boomsma, et al.
Cardiovascular Drugs and Therapy (2014) Vol. 28, Iss. 4, pp. 335-345
Closed Access | Times Cited: 13
Renin and prorenin as biomarkers in hypertension
A.H. Jan Danser
Current Opinion in Nephrology & Hypertension (2012) Vol. 21, Iss. 5, pp. 508-514
Closed Access | Times Cited: 13
Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, et al.
Expert Opinion on Drug Metabolism & Toxicology (2010) Vol. 7, Iss. 1, pp. 115-128
Closed Access | Times Cited: 10
Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity
Howard Weintraub, Daniel Duprez, William C. Cushman, et al.
Cardiovascular Drugs and Therapy (2012) Vol. 26, Iss. 2, pp. 145-155
Closed Access | Times Cited: 8
Primary and Secondary Hypertension
Jon D. Blumenfeld, Xiaodong Liu, John H. Laragh
Elsevier eBooks (2012), pp. 1670-1751
Closed Access | Times Cited: 8
Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition
Michael Ruddy
Postgraduate Medicine (2010) Vol. 122, Iss. 3, pp. 203-212
Closed Access | Times Cited: 7
Renin inhibitors in diabetes and hypertension: an update.
Selçuk Şen, Baran Ufuktepe, Zeynep Güneş Özünal, et al.
PubMed (2014) Vol. 13, pp. 1111-9
Closed Access | Times Cited: 6
Identifying treatment response to antihypertensives in patients with obesity-related hypertension
Ilse M. Schrover, Jannick A N Dorresteijn, Jodine E. Smits, et al.
Clinical Hypertension (2017) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Therapeutic Renin Inhibition in Diabetic Nephropathy—A Review of the Physiological Evidence
Bianca Domingues Massolini, Stephanie San Gregorio Contieri, Giulia Severini Lazarini, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 6
Using Plasma Renin (PRA) Testing to Design Follow-Up Drug Treatment Strategies in Hypertensive Patients Already Taking Antirenin System Drugs
J. E. Sealey, John H. Laragh
American Journal of Hypertension (2009) Vol. 22, Iss. 9, pp. 950-950
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top